All news from Pharmacology and Therapeutics
Childhood leukemia is a diagnosis that no family ever wants to endure. While the treatment of most types of leukemia has improved steadily over the years, a few specific types remain very difficult to treat. One of these is called "mixed-lineage leukemia," and the survival rate for children affected by this cancer is only around 50%
Researchers have designed a new way to grow nose cells in the lab heralding hope for sufferers of spinal cord injuries, including those who are wheelchair bound
A new clinical trial shows the benefits of an innovative form of radiation therapy, which delivers the radiation in only five sessions instead of the usual 37. The National Cancer Institute (NCI) estimated that prostate cancer affects over 160,000 people in the United States.
As children spend more time tethered to screens, there is increasing concern about potential harm to their visual development. Ophthalmologists—physicians who specialize in medical and surgical eye care—are seeing a marked increase in children with dry eye and eye strain from too much screen time
New York state has sued Purdue Pharma LP, accusing the OxyContin (oxycodone hydrochloride) maker of widespread fraud and deception in the marketing of opioid products, contributing to a nationwide epidemic that has killed thousands.
Higher PIRADS scores are associated with a higher likelihood of a diagnosis of prostate cancer, according to a retrospective study. The Prostate Imaging Reporting and Data System (PIRADS) score classifies MRI lesions on a scale from 1 to 5.
An aquarium fish that senses the Earth's magnetic field as it swims could help unlock how the human brain works and how diseases such as Parkinson's and other neurological disorders function.
More than two-thirds of women with ovarian cancer have high-grade serous carcinoma (HGSC). Up to 90 percent of HGSCs are not detected until they are beyond the ovaries or fallopian tubes, at which point it may not be possible to fully remove the tumor
Platelet-rich plasma (PRP) is believed to provide pain relief and help improve joint function in degenerative joint disease, a new study has shown that it does not act by promoting stem cell proliferation or enhance the cartilage formation capabilities of mesenchymal stem cells (MSCs).